Phase II Cervical Cancer Study with Advaxis’ Axalimogene Filolisbac Selected for Poster Discussion Session The poster, “ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the Phase II GOG/NRG0265 study,” was selected as one of 12 abstracts to be featured. [Press release from Advaxis, Inc. discussing research to be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release First Presentation of Overall Survival Data for Opdivo® (Nivolumab) Shows Significant Survival Benefit at One-Year versus Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Bristol-Myers Squibb Company announced the first presentation of data from CheckMate -141, a Phase III open-label, randomized trial, evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to investigator’s choice of therapy. [Press release from Bristol-Myers Squibb Company discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release Late Breaking Data from Advaxis Phase II Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform Advaxis, Inc. announced immunological and pathologic data from the company’s ongoing Phase II study of its lead immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with late-stage HPV-associated oropharyngeal cancer. [Press release from Advaxis, Inc. discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release Studies Show Continued Promise for Immunotherapy Drugs Several new immunotherapy drugs are continuing to show benefits across a range of cancer types, according to a slew of new data. The new results confirm their benefit for some melanoma patients, and also suggested they can help certain patients with head and neck cancers, and those with Merkel cell carcinoma. [Press release from Cancer Research UK discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release Clinical Data from IIT Using Medigene’s Dendritic Cell (DC) Vaccines in Prostate Cancer Presented Medigene AG announced that clinical data of a DC vaccine trial for the treatment of prostate cancer were presented. [Press release from Medigene AG discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release Immunotherapy Is First to Show Survival Benefit in Head and Neck Cancer The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [Press release from The Institute of Cancer Research discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release Biothera Pharmaceuticals Presents New Cancer Immunotherapy Research Biothera Pharmaceuticals, Inc. announced research providing new insights into the ability of the company’s Phase II cancer immunotherapy to coordinate innate and adaptive immune responses and enhance the effectiveness of combination therapies. [Press release from Biothera Pharmaceuticals, Inc. discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release Jounce Therapeutics Presents Data Highlighting Advances from Two Programs in Its Immuno-Oncology Pipeline Jounce Therapeutics, Inc. presented new preclinical data from two programs in the company’s immuno-oncology pipeline. Jounce’s first presentation highlighted JTX-2011, a humanized ICOS (inducible co-stimulator molecule) agonist antibody being developed for the treatment of solid tumors. [Press release from Jounce Therapeutics, Inc. discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release From our sponsor: Working with blood? Download the immune cell frequencies app. |